Effects of 1α-Calcidol (Alfacalcidol) on Microvascular Endothelial Function, Arterial Stiffness, and Blood Pressure in Type II Diabetic Nephropathy Patients

Microcirculation

Volumn 23, Issue 1, 2016, Pages 53-61

  Munisamy, Seetha ^a   Daud, Kamaliah M ^b   Mokhtar, Siti S ^a   Rasool, Aida H G ^a  

^a SCHOOL OF PHYSICS   (Malaysia)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Alfacalcidol; Arterial stiffness; Diabetic nephropathy; High sensitivity C reactive protein; Microvascular endothelial function

Indexed keywords

ALFACALCIDOL; C REACTIVE PROTEIN; CALCIUM; PHOSPHATE; HYDROXYCOLECALCIFEROL;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MEASUREMENT; CALCIUM BLOOD LEVEL; CENTRAL DIASTOLIC BLOOD PRESSURE; CENTRAL SYSTOLIC BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; ENDOTHELIUM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VITAMIN D DEFICIENCY; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; AGED; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; MIDDLE AGED; VASCULAR STIFFNESS; VITAMIN D DEFICIENCY;

EID: 84953924605     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/micc.12256     Document Type: Article

References (54)

1. Abularrage CJ, Sidawy AN, Aidinian G, Singh N, Weiswasser JM, Arora S. Evaluation of the microcirculation in vascular disease. J Vasc Surg 42: 574-581, 2005.
2. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L, Kavtaradze N, Uphoff I, Hooper C, Tangpricha V, Alexander RW, Brigham K, Quyyumi AA. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 58: 186-192, 2011.
3. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease. Hypertension 52: 249-255, 2008.
4. Alvarez JA, Gower BA, Calhoun DA, Judd SE, Dong Y, Dudenbostel T, Scholl J, Ashraf AP. Serum 25-hydroxyvitamin D and ethnic differences in arterial stiffness and endothelial function. J Clin Med Res 4: 197, 2012.
5. Andrade J, Er L, Ignaszewski A, Levin A. Exploration of association of 1, 25-OH2D3 with augmentation index, a composite measure of arterial stiffness. Clin J Am Soc Nephrol 3: 1800-1806, 2008.
6. Annavarajula SK, Dakshinamurty KV, Naidu Mur, Reddy CP. The effect of L-arginine on arterial stiffness and oxidative stress in chronic kidney disease. Indian J Nephrol 22: 340-346, 2012.
7. Carrara D, Bernini M, Bacca A, Rugani I, Duranti E, Virdis A, Ghiadoni L, Taddei S, Bernini G. Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. J Renin Angiotensin Aldosterone Syst 15: 82-87, 2014.
8. Chitalia N, Ismail T, Tooth L, Boa F, Hampson G, Goldsmith D, Kaski JC, Banerjee D. Impact of Vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS ONE 9: e91363, 2014.
9. Cupisti A, Rossi M, Placidi S, Fabbri A, Morelli E, Vagheggini G, Meola M, Barsotti G. Responses of the skin microcirculation to acetylcholine in patients with essential hypertension and in normotensive patients with chronic renal failure. Nephron 85: 114-119, 2000.
10. Di Cesar DJ, Ploutz-Snyder R, Weinstock RS, Moses AM. Vitamin D deficiency is more common in type 2 than in type 1 diabetes. Diabetes Care 29: 174, 2006.
11. Dong Y, Stallmann-Jorgensen IS, Pollock NK, Harris RA, Keeton D, Huang Y, Li K, Bassali R, Guo D-H, Thomas J, Pierce GL, White J, Holick MF, Zhu H. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab 95: 4584-4591, 2010.
12. Dong J, Wong SL, Lau CW, Lee HK, Ng CF, Zhang L, Yao X, Chen ZY, Vanhoutte PM, Huang Y. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J 33: 2980-2990, 2012.
13. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 15: 1983-1992, 2004.
14. Fadem SZ, Rosenthal B. MDRD Calculator (2000-2011, Nephron Information Center [Internet]. http://www.kidney.org/professional/kdoqi/gfr_calculator.cfm [Accessed 1 July 2013].
15. Foley R, Culleton B, Parfrey P, Harriett J, Kent G, Murray D, Barre P. Cardiac disease in diabetic end-stage renal disease. Diabetologia 40: 1307-1312, 1997.
16. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49: 1063-1069, 2007.
17. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168: 1174-1180, 2008.
18. Goel R, Lal H. Role of Vitamin D supplementation in hypertension. Indian J Clin Biochem 26: 88-90, 2011.
19. Hirata M, Serizawa K-I, Aizawa K, Yogo K, Tashiro Y, Takeda S, Moriguchi Y, Endo K, Fukagawa M. 22-Oxacalcitriol prevents progression of endothelial dysfunction through antioxidative effects in rats with type II diabetes and early-stage nephropathy. Nephrol Dial Transplant 28: 1166-1174, 2013.
20. Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 267: 462-472, 2010.
21. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 87: 136-141, 2008.
22. Kannel WB, McGee DL. Diabetes and Cardiovascular Disease. JAMA 241: 2035-2038, 1979.
23. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens 17: 986-993, 2004.
24. Keane WF, Brenner BM, De Zeeuw D, Grunfeld J-P, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int 63: 1499-1507, 2003.
25. Kilkkinen A, Knekt P, Aro A, Rissanen H, Marniemi J, Heliavaara M, Impivaara O, Reunanen A. Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol 170: 1032-1039, 2009.
26. Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens 25: 1215-1222, 2012.
27. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89-90: 387-392, 2004.
28. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Mëtivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18: 613-620, 2007.
29. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin A., Newby DE, Cockcroft JR, Wilkinson IB. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 48: 602-608, 2006.
30. Mullan BA, Young IS, Fee H, McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 40: 804-809, 2002.
31. Munisamy S, Kamaliah MD, Suhaidarwani AH, Zahiruddin WM, Rasool AH. Impaired microvascular endothelial function in vitamin D-deficient diabetic nephropathy patients. J Cardiovasc Med 14: 466-471, 2012.
32. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 15: 426-444, 2002.
33. Orwoll ES, Oviatt S. Relationship of mineral metabolism and long-term calcium and cholecalciferol supplementation to blood pressure in normotensive men. Am J Clin Nutr 52: 717-721, 1990.
34. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86: 1633-1637, 2001.
35. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 50: 197-203, 2007.
36. Salum E, Kampus P, Zilmer M, Eha J, Butlin M, Avolio A, Põdramägi T, Arend A, Aunapuu M, Kals J. Effect of vitamin D on aortic remodeling in streptozotocin-induced diabetes. Cardiovasc Diabetol 11: 58, 2012.
37. Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 49: 640, 1995.
38. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19: 179-184, 2004.
39. Sokolnicki LA, Roberts SK, Wilkins BW, Basu A, Charkoudian N. Contribution of nitric oxide to cutaneous microvascular dilation in individuals with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 292: E314-E318, 2007.
40. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N. 25-Hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111: 1666-1671, 2005.
41. Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34: 55-68, 1997.
42. Stewart J, Kohen A, Brouder D, Rahim F, Adler S, Garrick R, Goligorsky MS. Noninvasive interrogation of microvasculature for signs of endothelial dysfunction in patients with chronic renal failure. Am J Physiol Heart Circ Physiol 287: H2687-H2696, 2004.
43. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25: 320-325, 2008.
44. Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J, Rashid G. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 294: F1059-F1064, 2008.
45. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-court D, Aganna E, Price CP, Boucher BJ. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 95: 787-796, 2002.
46. Uberti F, Lattuada D, Morsanuto V, Nava U, Bolis G, Vacca G, Squarzanti DF, Cisari C, Molinari C. Vitamin D protects human endothelial cells from oxidative stress through the autophagic and survival pathways. J Clin Endocrinol Metab 99: 1367-1374, 2014.
47. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511, 2008.
48. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D3 on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 53: 2112-2119, 2010.
49. Wong MSK, Delansorne R, Man RYK, Svenningsen P, Vanhoutte PM. Chronic treatment with vitamin D lowers arterial blood pressure and reduces endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 299: H1226-H1234, 2010.
50. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 186: 20-28, 2006.
51. Yiu Y-F, Yiu K-H, Siu C-W, Chan Y-H, Li S-W, Wong L-Y, Lee SWL, Tam S, Wong EWK, Lau C-P, Cheung BMY, Tse H-F. Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. Atherosclerosis 227: 140-146, 2013.
52. Zagura M, Serg M, Kampus P, Zilmer M, Eha J, Unt E, Lieberg J, Cockcroft JR, Kals J. Aortic stiffness and vitamin D are independent markers of aortic calcification in patients with peripheral arterial disease and in healthy subjects. Eur J Vasc Endovasc Surg 42: 689-695, 2011.
53. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci 105: 15896-15901, 2008.
54. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 92: 39-48, 2006.